AbbVie Advances Obesity Pipeline With Completion of First-in-Human GUB014295 Trial

Abbvie (ABBV) announced an update on their ongoing clinical study.

Study Overview: AbbVie has completed a first-in-human trial titled “A Two-Part First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Subcutaneous Doses of GUB014295 in Lean to Overweight or Obese But Otherwise Healthy Men and Women.” The study aims to understand how safe the new drug GUB014295 is, how well people tolerate it, and how the body absorbs and processes it. This early safety work in healthy and overweight volunteers is a key step before testing in patients with weight-related conditions and could open a new front in metabolic and obesity care.

Intervention/Treatment: The main treatment is GUB014295, a long-acting amylin analogue given by subcutaneous injection. It is designed to help control appetite and weight, similar in concept to other hormone-based weight drugs, but using the amylin pathway. A matching placebo injection is also used to compare effects and side effects against no active drug.

Study Design: This is a Phase 1, randomized trial in two parts. Volunteers are randomly placed into groups that receive either GUB014295 or placebo. Doses increase over time, first as single doses, then as repeated doses. The study is double-blind, which means participants, doctors, and those assessing outcomes do not know who gets the real drug or placebo. The main purpose is treatment-focused safety testing, not yet to show full weight-loss benefit.

Study Timeline: The trial was first submitted in November 2023, signaling AbbVie’s formal move of GUB014295 into human testing. The overall study status is now marked as completed, indicating dosing and follow-up are done. No results have been posted yet, but the latest update on January 14, 2026, shows AbbVie is actively maintaining the record and likely preparing data for disclosure or next-phase planning. Final estimated completion aligns with this update window, making the coming months important for data release.

Market Implications: For investors, the completion of this early study reduces some development risk around GUB014295’s basic safety, a critical gate for any metabolic or obesity drug. While there are no results yet, a clean safety profile could support AbbVie’s strategy to build a presence in high-growth obesity and metabolic markets currently led by players such as Eli Lilly and Novo Nordisk. Even modest positive signals could lift sentiment toward AbbVie’s longer-term pipeline value, especially if the company confirms plans for Phase 2 trials. Conversely, any safety issues or lack of meaningful pharmacodynamic signals could weigh on expectations and support the competitive edge of existing leaders. Overall, the update supports a cautious but constructive view on AbbVie’s optionality in the obesity and metabolic space.

The study has been completed and recently updated, with further details and future results to be made available on the ClinicalTrials.gov portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.